CytomX Therapeutics, Inc. - 8-K Filing
CytomX Therapeutics stockholders approved amendments on June 17, 2026, increasing authorized shares under its equity incentive plan by 6.5 million and employee stock purchase plan by 1 million. The company also increased the total common stock authorization from 300 million to 600 million as part of a charter amendment approved at the annual meeting. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, 5.07 Submission of Matters to a Vote of Security Holders, 9.01 Financial Statements and Exhibits)
Tickers: $CTMX